Integra LifeSciences-2026 JPM.pdf

1、Integra LifeSciencesJ.P.Morgan Healthcare ConferenceJanuary 2026Slide 2Forward-looking statementsA global medtech leader dedicated to restoring livesDemonstrated leadership in$9B global marketExtensive portfolio of best-in-class productsExecuting strategic transformation Strengthening operational fo

2、undationEnabling growth and innovationSlide 319%LTM adjustedEBTIDA margin62.8%LTM adjustedgross margin$1.6BLTM reportedrevenue$89MLTM operating cash flowFinancial metrics shown for the trailing 12-months ended Sept.30,2025Both adj.gross margin and adj.EBITDA margin are non-GAAP financial measuresNeu

3、rosurgery&ENT$3.4BMid-single-digit growthTAM$9.1BMid-single-digit growthComplex Wound ReconstructionSurgical ReconstructionPrivate LabelGlobal OpportunityCodman Specialty Surgical(CSS)$1.1B1Tissue Technologies(TT)$0.5B1Instruments$2.1BLow-single-digit growthWound&Surgical Recon$3.6BMid-to-high-singl

4、e-digit growthENTInstrumentsNeurosurgerySlide 4Leadership in large global marketsHighly differentiated products trusted by healthcare professionals and systems1Trailing 12-months ended Sept.30,2025Our right to win in attractive core marketsAddressing key market trends with differentiated capabilitie

5、sSlide 5Healthcare market trendsIntegras right to winDisease states driven by demographicsShifting point-of-care to alternate care settingsGrowing adoption of new technologiesChanging reimbursement landscapeGeopolitical driversOpportunities in international marketsCommercial excellenceNeurosurgery l

6、eadershipStrong brand equityDeep scientific expertise in tissue reconstructionClinically differentiated productsAdvancing transformational care,delivering impactful innovation,and enriching life moments.Slide 6Our visionDelivering our visionDeliver best-in-class qualityIgniteinnovationIntegras strat